Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study. M. SALGADO, M. REBOREDO, J. C. MENDEZ, G. QUINTERO, M. L. PELLÓN, C. ROMERO, M. JORGE, A. F. MONTES, M. VALLADARES-AYERBES, M. RAMOS, S. VARELA, M. Á. ALONSO (Ourense; A Coruña; Ferrol; Vigo, Spain) ................................................................. 4089

Urinary Neopterin Concentration and Toxicity of Radiotherapy in Patients with Head and Neck Carcinoma During External Beam Radiation. P. HOLEČKOVÁ, L. KRČMOVÁ, J. LÉTAL, A. SVOBODNÍK, H. KALÁBOVÁ, M. KAŠPAROVÁ, J. PLÍŠEK, M. PÁLA, P. VÍTEK, P. SOLICHOVÁ, M. ZEZULOVÁ, H. ŠTUDENTOVÁ, M. DOLEŽEL, B. MELICHAR (Prague; Hradec Králové; Brno; Olomouc; Czech Republic) ................................................................. 4097

Aberrant Expression of CXCR4 and β-Catenin in Pancreatic Cancer. Z. WANG, Q. MA, P. LI, H. SHA, X. LI, J. XU (Xi’an, P.R. China) ............................................................................................................................................... 4103

Anal Carcinoma: Surgery Does Not Influence Prognosis When Performed Prior to Concurrent Radiochemotherapy. H. BADAKHSHI, V. BUDACH, P. WUST, R. GRAF (Berlin, Germany) ................................................................. 4111

Image-guided Radiotherapy with Implanted Markers and Kilovoltage Imaging and 6-dimensional Position Corrections for Intrafractional Motion of the Prostate. H. BADAKHSHI, P. WUST, V. BUDACH, R. GRAF (Berlin, Germany) ................................................................. 4117

Prognostic Factors of Metastatic or Recurrent Esophageal Squamous Cell Carcinoma in Patients Receiving Three-drug Combination Chemotherapy. W.-W. CHEN, C.-C. LIN, T.-C. HUANG, A.-L. CHENG, K.-H. YEH, C.-H. HSU (Taipei; Yunlin, Taiwan, R.O.C) ............................................................................................................. 4123


Errata ............................................................................................................................................................................. 4135


E6/E7 mRNA Expression of High-risk HPV Types in 849 Greek Women. E. ARGYRI, E. TSIMPLAKI, D. DASKALOPOULOU, D. J. STRAVOPODIS, O. KOUIKOGLOU, E. TERZAKIS, E. PANOTOPOULOU (Athens, Greece) .......................................................... 4007


Water Swallow Screening Test for Patients After Surgery for Head and Neck Cancer: Early Identification of Dysphagia, Aspiration and Limitations of Oral Intake. C. HEY, B. P. LANGE, S. EBERLE, Y. ZARETSKY, R. SADER, T. STÖVER, J. WAGENBLAST (Frankfurt/Main; Göttingen, Germany) ........ 4017


Feasibility Study of Oxaliplatin with Oral S-1 or Capecitabine as First-line Therapy for Patients with Metastases from Colorectal Cancer. K. WATANABE, H. KAWAHARA, H. ENOMOTO, Y. TOYAMA, T. AKIBA, K. YANAGA (Chiba; Tokyo, Japan) .................................................. 4029


Genetic Profile and Determinants of Homocysteine Levels in Kazakhstan Patients with Breast Cancer. A. AKILZHANOVA, Z. NURKINA, K. MOMYNALIEV, E. RAMANCULOV, Z. ZHUHADILOV, T. RAKHYPBEKOV, N. HAYASHIDA, M. NAKASHIMA, N. TAKAMURA (Nagasaki, Japan; Astana; Semey, Kazakhstan) ........................................................................... 4049

Bevacizumab as Front-line Treatment of Brain Metastases from Solid Tumors: A Case Series. F. ZUSTOVICEH, A. FERRO, G. LOMBARDI, V. ZAGONEL, P. FIDUCCIA, P. FARINA (Padua, Italy) ....... 4061


Content continued on the preceding page

Circulating Tumor Cell (CTC) Count and Epithelial Growth Factor Receptor Expression on CTCs as Biomarkers for Cetuximab Efficacy in Advanced Colorectal Cancer. Y. KUBOKI, S. MATSUSAKA, S. MINOWA, H. SHIBATA, M. SUEYAGA, E. SHINOZAKI, N. MIZUNUMA, M. UENO, T. YAMAGUCHI, K. HATAKE (Tokyo, Japan) .......................................................... 3905

A Rare Occurrence of Biphasic Pulmonary Blasiaoma in an Elderly Male. A. SHARMA, K. O’GORMAN, C. AMAN, D. RASSL, W. MOHAMID, A. POLYCHRONIS (Northwood; Cambridge; Stevenage, U.K.) ......... 3911

Consideration of Primary Diseases and Concomitant Therapies. A. T. ASSAF, R. SMEETS, B. RIECKE, E. WEISE, A. GRÖBE, M. BLESSMANN, T. STEINER, J. WIKNER, R. E. FRIEDRICH, M. HEILAND, F. HOELZLE, F. GERHARDS (Hamburg; Aachen, Germany) .............................................................. 3917


The Surgeon as the Most Important Factor in Lymph Node Harvest During Axillary Clearane. D. N. NAUMANN, M. SINTLER (Birmingham, U.K.) ........................................................................................................ 3935

Impact of Chemotherapy with S-1 and Oxaliplatin (SOX) in Combination with Molecular-targeting Agents on Colorectal Liver Metastases. K. WATANABE, H. KAWAHARA, H. ENOMOTO, Y. TOYAMA, T. AKIBA, K. YANAGA (Chiba; Tokyo, Japan) ........................................................................................................ 3941

A High Serum Uric Acid Level is Associated with Poor Prognosis in Patients with Acute Myeloid Leukemia. T. YAMÁUCHI, E. NEGORO, S. LEE, M. TAKAI, Y. MATSUDA, K. TAKAGI, S. KISHI, K. TAI, N. HOSONO, T. TASAKI, S. IKEGAYA, K. INAI, A. YOSHIDA, Y. USASAKI, H. IWASAKI, T. UEDA (Eiheiji, Japan) ....... 3947

Prognostic Value of Nuclear Translocation of Aryl Hydrocarbon Receptor for Non-small Cell Lung Cancer. J. -M. SU, P. LIN, H. CHANG (Taichung; Zhunan, Taiwan, R.O.C.) ........................................................................................................ 3953

Comparisons of Late Vaginal Mucosal Reactions Between Intertstitial and Conventional Intracavitary Brachytherapy in Patients with Gynecological Cancer: Speculation on the Relation Between Pallor Reaction and Stenosis. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, S. J. BAEK, H. AKIYAMA, E. TANAKA, Y. YOSHIKOA (Takatsuki; Kyoto; Osaka; Suita, Japan) ............................................................ 3963

Podoplanin and VEGF-C Immunoexpression in Oral Squamous Cell Carcinomas: Prognostic Significance. A. D. S. ALMEIDA, D. T. OLIVEIRA, M. C. PEREIRA, S. E. S. FAUSTINO, S. NONOGAKI, A. L. CARVALHO, L. P. KOWALSKI (Bauru; Divinópolis; São Paulo; Barretos, Brazil) ........................................................................................................ 3969


Contents continued on the preceding page

Vascular Endothelial Growth Inhibitor (VEGI) Is an Independent Indicator for Invasion in Human Pituitary Adenomas. W. JIA, A. J. SANDER, G. JIA, M. NI, X. LIU, R. LU, W. G. JIANG (Beijing, P. R. China; Cardiff, U.K.) ............................................................. 3815

Clinical Studies


Docetaxel in the Treatment of Non-small Cell Lung Cancer (NSCLC) – An Observational Study Focusing on Symptom Improvement. A. PIRCHER, I. K. WASLE, M. MIAN, G. GAMERITH, E. ULSPERGER, M. STUDNICKA, A. MOHN-STAUDNER, W. HILBE, M. FIEGL (Innsbruck; Vienna; Salzburg, Austria) ............. 3831

Efficacy of Combined Androgen Blockage with Zoledronic Acid Treatment in Prostate Cancer with Bone Metastasis: The ZABTON-PC (Zoledronic Acid/Androgen Blockade Trial on Prostate Cancer) Study. S. UENO, A. MIZOKAMI, T. FUKAGAI, N. FUJIMOTO, H. OH-OKA, Y. KONDO, G. ARAI, H. IDE, S. HORIE, O. UEKI, K. KAWAGUCHI, M. SHIMAMURA, M. ORITO, T. ISHIDA, D. IKEDA, M. NAMIKI (Kanazawa; Tokyo; Fukuoka; Kobe; Koshigaya; Nanao; Takaoka, Japan) .............................................. 3837

Pharmacokinetic Assessment of Irinotecan, SN-38, and SN-38-Glucuronide: A Substudy of the FIRIS Study. T. SATOH, H. YASUI, K. MURO, Y. KOMATSU, S. SAMESHIMA, K. YAMAGUCHI, K. SUGIHARA (Suita; Shizuoka; Nagoya; Sapporo; Saitama; Tokyo, Japan) .......................................................... 3845

Immunological Response after WT1 mRNA-loaded Dendritic Cell Immunotherapy in Ovarian Carcinoma and Carcinosarcoma. A. COOSEMANS, A. VANDERSTRAETEN, S. TUYAERTS, T. VERSCHUERE, P. MOERMAN, Z. BERNEMAN, I. VERGOTE, F. AMANT, S. W. VAN GOOL (Leuven; Antwerp, Belgium) ........................................................................................................ 3855

Vitamin D Favorably Alters the Cancer Promoting Prostaglandin Cascade. W. QIN, C. SMITH, M. JENSEN, M. F. HOLICK, E. R. SAUTER (Tyler, TX; Fargo, ND; Boston, MA, U.S.A.)............................. 3861

Morbid Obesity Does Not Disadvantage Patients with In Situ or Early-stage Carcinoma Undergoing Breast-conserving Surgery. F. AMPIL, G. CAL DIGO, B. LI, S. DEVARAKONDA, G. BURTON, R. H. KIM, Q. CHU (Shreveport, LA, U.S.A.) .................................................................................. 3867

In Vitro Demonstration of Synergy/Additivity Between 188Rhenium and Sorafenib on Hepatoma Lines: Preliminary Results. M. PRACHT, J. EDELINE, N. LEPAREUR, L. LENOIR, V. ARDISSON, B. CLEMENT, J.-L. RAOUL, O. AUDRAIN, E. BOUCHER, E. GARIN (Rennes; Marseille, France) ............... 3871


Number of Involved Extracranial Organs Predicts Survival in Patients with Brain Metastasis from Small Cell Lung Cancer. L. GERDAN, B. ŠEGEDIN, T. VENINGA, S. E. SCHILD, D. RADES (Lübeck, Germany; Ljubljana, Slovenia; Tilburg, the Netherlands; Scottsdale, AZ, U.S.A.) ........................................ 3887

Definition of p53 Overexpression and its Association with the Clinicopathological Features in Luminal/HER2-negative Breast Cancer. S. KIKUCHI, R. NISHIMURA, T. OSAKO, Y. OKUMURA, Y. NISHIYAMA, Y. TOYOZUMI, N. ARIMA (Kumamoto, Japan) .................................................................. 3891

Contents continued on the preceding page

Differential Expression of p-mTOR in Cutaneous Basal and Squamous Cell Carcinomas Likely Explains their Different Response to mTOR Inhibitors in Organ-transplant Recipients. G. KARAYANNOPOULOU, S. EUVRARD, J. KANITAKIS (Thessaloniki, Greece; Lyon, France) .......................................................... 3711

Tumor–stromal Interactions with Direct Cell Contacts Enhance Motility of Non-small Cell Lung Cancer Cells Through the Hedgehog Signaling Pathway. C. CHOE, Y. -S. SHIN, S. -H. KIM, M. -J. JEON, S. -J. CHOI, J. LEE, J. KIM (Seoul, Republic of Korea) .......................................................... 3715

The Diagnostic Value of Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Measurement in the Sera of Patients with Endometrial Cancer. K. ORYWAL, W. JELSKI, M. ZDRODOWSKI, M. SZMITKOWSKI (Bialystok, Poland) .......................................................... 3725


Antitumorigenic Effect of Dietary Natural Compounds via Lipid Metabolism Modulation in ApoMin/+ Mice. M. NOTARNICOLA, V. TUTINO, A. TAFARO, F. AMATULLI, M. G. CARUSO (Bari, Italy) .......................................................... 3739


Combination of the EGFR Tyrosine Kinase Inhibitor AG1478 and 5-FU: No Synergistic Effect on EGFR Phosphorylation, Cell Proliferation and Apoptosis Induction. V. YAGUBLU, Z. AHMADOVA, Y. HAJIYEVA, M. HAFNER, M. KEESE (Mannheim; Frankfurt, Germany) .......................................................... 3753

PTK7 Expression in Triple-negative Breast Cancer. B. ATASEVEN, R. ANGERER, R. KATES, A. GUNESCH, P. KNAYZEV, B. HÖGEL, C. BECKER, W. EIERMANN, N. HARBECK (Munich; Essen; Martinsried, Germany) .......................................................... 3759

Frequent Promoter Methylation of CDH1 in Non-neoplastic Mucosa of Sporadic Diffuse Gastric Cancer. K. H. LEE, D. HWANG, K. Y. KANG, S. LEE, D. Y. KIM, Y. E. JOO, J. H. LEE (Gwangju; Namwon, Republic of Korea) .......................................................... 3765


Macrophage Apolipoprotein E and Proliferation of MCF-7 Breast Cancer Cells: Role of LXR. A. EL ROZ, J. -M. BARD, S. VALIN, J. -M. HUVELIN, H. NAZIH (Nantes, France) .......................................................... 3783

Lewis Lung Carcinoma Progression Is Facilitated by TIG-3 Fibroblast Cells. Y. YAMAUCHI, Y. IZUMI, K. ASAKURA, K. KAWAI, M. WAKUI, M. OHMURA, M. SUEMATSU, H. NOMORI (Tokyo; Kanagawa, Japan) .......................................................... 3791

Multiple Anticancer Effects of Damsin and Coronopilin Isolated from Ambrosia arborescens on Cell Cultures. R. VILLAGOMEZ, G. C. RODRIGO, L. G. COLLADO, M. A. CALZADO, E. MUÑOZ, B. ÅKESSON, O. STERNER, G. R. ALMANZA, R. -D. DUAN (La Paz, Bolivia; Lund, Sweden; Cadiz; Córdoba, Spain) .......................................................... 3799

Contents continued on the preceding page
Efficacy of Liposomal Curcumin in a Human Pancreatic Tumor Xenograft Model: Inhibition of Tumor Growth and Angiogenesis. A. P. RANJAN, A. MUKERJEE, L. HELSON, R. GUPTA, J. K. VISHWANATHA (Fort Worth, TX; Quakertown, PA, U.S.A.) ................................................................. 3603

Stable Knockdown of hCGβ mRNA Expression in Bladder Cancer Cells Results in Significant Growth Inhibition. B. BURCZYNSKA, M. J. BOOTH, R. K. ILES, A. SHAH, A. SHILED, S. A. BUTLER (London; Crieff, Scotland, U.K.; Poznan, Poland) ................................................................................................................................. 3611

Antitumor Activity of Elacytarabine Combined with Bevacizumab, Cetuximab and Trastuzumab in Human NSCLC Xenografts. S. BRUHEIM, M. L. SANDVOLD, G. M. MÆLANDSMO, Ø. FODSTAD (Oslo, Norway) ........................................................................................................................................ 3615

High Lung-metastatic Variant of Human Osteosarcoma Cells, Selected by Passage of Lung Metastasis in Nude Mice, Is Associated with Increased Expression of αvβ3 Integrin. Y. TOME, H. KIMURA, H. MAEHARA, N. SUGIMOTO, M. BOUVET, H. TSUCHIYA, F. KANAYA, R. M. HOFFMAN (San Diego, CA, U.S.A.; Okinawa; Kanazawa, Japan) .................................................................................................................................. 3623

Effect of Liposomal Curcumin on Red Blood Cells In Vitro. A. STORKA, B. VCELAR, U. KLICKOVIC, G. GOUYA, S. WEISSHAAR, S. ASCHAUER, L. HELSON, M. WOLZT (Vienna; Klosterneuburg, Austria; Quakertown, PA, U.S.A.) ...................................................................................................................... 3629


Enhanced Redox Factor 1 (REF1)-modulated p53 Stabilization and JNK1 Dissociation in Response to Selenomethionine. H. J. JUNG, H. L. KIM, Y. R. SEO (Bronx, NY, U.S.A.; Seoul, Republic of Korea) .... 3645


Malignant Progressive Tumor Cell Clone Exhibits Significant Up-regulation of Cofilin-2 and 27-kDa Modified Form of Cofilin-1 Compared to Regressive Clone. Y. KURAMITSU, Y. WANG, F. OKADA, B. BARON, K. TOKUDA, T. KITAGAWA, J. AKADA, K. NAKAMURA (Ube; Yonago, Japan) ............. 3661

Effects of Dietary Calcium on Helicobacter pylori-induced Gastritis in Mongolian Gerbils. M. IIMURO, S. NAKAMURA, T. ARAKAWA, K. WAKABAYASHI, M. MUTOH (Hyogo; Osaka; Shizuoka; Tokyo, Japan) .... 3667

Vagus Nerve Regulates Breast Cancer Metastasis to the Adrenal Gland. N. ERIN, G. A. BARKAN, G. A. CLAWSON (Antalya, Turkey; Maywood, IL; Hershey, PA, U.S.A.) .................................................................................................................................. 3675


Tropomyosin-related Kinase B Inhibitor Has Potential for Tumor Regression and Relapse Prevention in Pulmonary Large Cell Neuroendocrine Carcinoma. S. ODATE, H. ONISHI, K. NAKAMURA, M. KOJIMA, A. UCHIYAMA, M. KATO, M. KATANO (Fukuoka, Japan) .................................................................................................................................. 3699

Contents continued on the preceding page